C22-103-11 rHuEMAP-II說明書

Catalog Number: C22-103-11
Source:  Escherichia coli.
Molecular Weight:  Approximately 18.3 KDa, a single non-glycosylated polypeptide chain containing 166 amino acids.
Quantity:  5μg/20μg/1000μg
AA Sequence:  SKPIDVSRLD LRIGCIITAR KHPDADSLYV EEVDVGEIAP RTVVSGLVNH VPLEQMQNRM
 VILLCNLKPA KMRGVLSQAM VMCASSPEKI EILAPPNGSV PGDRITFDAF PGEPDKELNP
 KKKIWEQIQP DLHTNDECVA TYKGVPFEVK GKGVCRAQTM SNSGIK
Purity:  >98% by SDS-PAGE and HPLC analyses.
Biological Activity:  Fully biologically active when compared to standard. The ED50 determined by the apoptotic effect
 using serum free human MCF-7 cells is less than 40 ng/ml, corresponding to a specific activity of＞ 2.5 × 104 IU/mg.
Physical Appearance:  Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation:  Lyophilized from a 0.2μm filtered concentrated solution in 20mM PB, pH 7.4, 130mM NaCl.
Endotoxin:  Less than 1EU/μg of rHuEMAP-II as determined by LAL method.
Reconstitution:  We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the
 bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a
 concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and
 stored at <-20°C. Further dilutions should be made in appropriate buffered solutions.
Storage:  This lyophilized preparation is stable at 2-8°C, but should be kept at -20°C for long term storage,
 preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8°C. For
 maximal stability, apportion the reconstituted preparation into working aliquots and store at -20°C to
 -70°C. Avoid repeated freeze/thaw cycles.
Usage:  This material is offered by Shanghai Corning Bio-Tech for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE.

Human Endothelial-Monocyte Activating Polypeptide II
Endothelial-Monocyte Activating Polypeptide II (EMAP-II) is a tumor derived cytokine that exerts a wide range of activities on
endothelial cells, monocytes and neutrophils. EMAP-II inhibits endothelial cell proliferation, vasculogenesis, neovessel
formation, and can induce apoptosis. It is also chemotactic towards neutrophils and monocytes and induces myeloperoxidase
activity from neutrophils. Of clinical importance, EMAP-II inhibits angiogenesis of vascular beds and suppresses the growth of
primary and secondary tumors without affecting normal tissues. Mature EMAP-II is an 18.3 kDa protein, which is synthesized as
the C-terminal portion of a biologically inactive precursor protein containing a propeptide of 146 amino acid residues.